1 More recently.

Analyses were performed according to the intention-to-treat basic principle. A Cox proportional-hazards regression analysis21 was utilized to estimate P values and hazard ratios, with 99 percent confidence intervals to take into account the five comparisons defined in the amendment of April 2005. We used cumulative-incidence estimates22 to control for competing risks. The significance of differences in the incidence of adverse events among the four treatment groupings was assessed by using Fisher’s exact test; these analyses were not altered for multiple comparisons.And Europe and our recent growth into international markets in South and Asia America, Accuri is now among the fastest growing cell analysis companies worldwide,’ said Jeffrey Williams, CEO and President of Accuri.’ Accuri is currently implementing an ISO13485 Quality System in preparation for the prepared European launch of the Accuri C6 Flow Cytometer with CE-IVD mark qualification for clinical make use of, to be accompanied by a 510 regulatory submission to the Food & Drug Administration seeking clearance to advertise the Accuri C6 Flow Cytometer for scientific IVD applications in the U.S.